caa a22 4500 445332727 CHVBK 20180317142742.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1245/s10434-010-1288-5 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1288-5 Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study [Elektronische Daten] [Robert Martin, Jonathan Joshi, Ken Robbins, Dana Tomalty, Petar Bosnjakovik, Milous Derner, Radek Padr, Miloslav Rocek, Alexander Scupchenko, Cliff Tatum] Introduction: Response rates and overall outcome for patients who have failed first-line and in some cases second-line chemotherapy are as low as 12% and 7months, respectively. The aim of this study is to evaluate the efficacy of hepatic arterial sulfonate hydrogel microsphere (drug-eluting beads), irinotecan preloaded therapy (DEBIRI) in metastatic colorectal cancer refractory to systemic chemotherapy. Methods: This was a multicenter multinational single-arm study of metastatic colorectal cancer patients who received DEBIRI after failing systemic chemotherapy from 10/2006 to 8/2008. Primary endpoints were safety, tolerance, tumor response rates, and overall survival. Results: Fifty-five patients who had received prior systemic chemotherapy and who underwent a total of 99 DEBIRI treatments were reviewed. The median number of DEBIRI treatments was 2 (range 1-5), median treatment dose was 100mg (range 100-200mg), with total hepatic treatment of 200mg (range 200-650mg), with 86% of treatments performed as lobar infusion and 30% of patients treated with concurrent simultaneous chemotherapy. Adverse events occurred in 28% of patients with median grade of 2 (range 1-3) with no deaths at 30days post procedure. Response rates were 66% at 6months and 75% at 12months. Overall survival in these patients was 19months, with progression-free survival of 11months. Conclusions: Hepatic arterial drug-eluting bead, irinotecan (DEBIRI) was safe and effective in treatment of metastatic colorectal cancer (MCC) refractory to multiple lines of systemic chemotherapy. DEBIRI is an acceptable therapy for treatment of metastatic colorectal cancer to the liver. Society of Surgical Oncology, 2010 Martin Robert Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY, USA aut Joshi Jonathan Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY, USA aut Robbins Ken Baptist Health, Little Rock, AR, USA aut Tomalty Dana Huntsville Hospital, Huntsville, AL, USA aut Bosnjakovik Petar Institute of Radiology, University Clinical Center, Nis, Serbia aut Derner Milous Institute of Clinical and Interventional Radiology, Usti Nad Labem, Czech Republic aut Padr Radek Departments of Radiology, Pediatric Hematology, and Oncology, University Hospital Motol and 2nd Medical Faculty, Charles University, Prague, Czech Republic aut Rocek Miloslav Department of Diagnostic and Interventional Radiology, Institute of Clinical and Interventional Radiology (IKEM), Prague 4, Czech Republic aut Scupchenko Alexander Regional Oncological Dispenser, Samara, Russia aut Tatum Cliff Norton Radiology, Louisville, KY, USA aut Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 192-198 1068-9265 18:1<192 2011 18 10434 https://doi.org/10.1245/s10434-010-1288-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1288-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Martin Robert Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY, USA aut NATIONALLICENCE 700 1- Joshi Jonathan Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY, USA aut NATIONALLICENCE 700 1- Robbins Ken Baptist Health, Little Rock, AR, USA aut NATIONALLICENCE 700 1- Tomalty Dana Huntsville Hospital, Huntsville, AL, USA aut NATIONALLICENCE 700 1- Bosnjakovik Petar Institute of Radiology, University Clinical Center, Nis, Serbia aut NATIONALLICENCE 700 1- Derner Milous Institute of Clinical and Interventional Radiology, Usti Nad Labem, Czech Republic aut NATIONALLICENCE 700 1- Padr Radek Departments of Radiology, Pediatric Hematology, and Oncology, University Hospital Motol and 2nd Medical Faculty, Charles University, Prague, Czech Republic aut NATIONALLICENCE 700 1- Rocek Miloslav Department of Diagnostic and Interventional Radiology, Institute of Clinical and Interventional Radiology (IKEM), Prague 4, Czech Republic aut NATIONALLICENCE 700 1- Scupchenko Alexander Regional Oncological Dispenser, Samara, Russia aut NATIONALLICENCE 700 1- Tatum Cliff Norton Radiology, Louisville, KY, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/1(2011-01-01), 192-198 1068-9265 18:1<192 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer